Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;2(3):326-31.
doi: 10.4103/0975-1483.66807.

Drug interaction and pharmacist

Ja Ansari  1
Affiliations

Drug interaction and pharmacist

Ja Ansari. J Young Pharm. 2010 Jul.

Abstract

The topic of drug-drug interactions has received a great deal of recent attention from the regulatory, scientific, and health care communities worldwide. Nonsteroidal anti-inflammatory drugs, antibiotics and, in particular, rifampin are common precipitant drugs prescribed in primary care practice. Drugs with a narrow therapeutic range or low therapeutic index are more likely to be the objects for serious drug interactions. Object drugs in common use include warfarin, fluoroquinolones, antiepileptic drugs, oral contraceptives, cisapride, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. The pharmacist, along with the prescriber has a duty to ensure that patients are aware of the risk of side effects and a suitable course of action should they occur. With their detailed knowledge of medicine, pharmacists have the ability to relate unexpected symptoms experienced by patients to possible adverse effects of their drug therapy.

Keywords: Computerized screening systems; current indian scenario of drug interactions; drug interaction management; drug interactions.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Farkas D, Shader RI, von Moltke LL, Greenblatt DJ. Mechanisms and consequences of drug-drug interactions. In: Gad SC, editor. Preclinical Development Handbook: ADME and Biopharmaceutical Properties. Philadelphia: Wiley; 2008. pp. 879–917.
    1. Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician. 2000;61:1745–54. - PubMed
    1. Montané E, Barriocanal A, Isern I, Parajon T, Costa J. Multiple drug interactions-induced serotonin syndrome: A case report. J Clin Pharm Ther. 2009;34:485–7. - PubMed
    1. MedWatch-What Is A Serious Adverse Event? Available from: http://www.fda.gov/medwatch/report/DESK/advevnt.htm [last retrieved on 2007 Sep 18]
    1. Clinical Drug Use. Available from: http://www.clinicaldruguse.com/ [last retrieved on 2007 Sep 18]